hrp0095p1-330 | Growth and Syndromes | ESPE2022

The JAMP (Journey around Achondroplasia Medicines and Patients) Project: Results Collected From Two Surveys to clinicians and Patients in Italy

Antoniazzi Franco , Francesca Bedeschi Maria , Boero Silvio , LidonniciDario , Maghnie Mohamad , MoraStefano , Ravasio Roberto , Scarano Gioacchino , Selicorni Angelo , Sessa Marco , Verdoni Fabio , Zampino Giuseppe

Achondroplasia is a rare genetic condition caused by a recurrent pathogenetic variant in the FGFR3 gene resulting in short limb skeletal dysplasia. Due to the wide-ranging anomalies associated with achondroplasia (both peculiar clinical features and complications), a multidisciplinary team is often required for ongoing care, although the nature of specialists involved differs among countries. Despite a European consensus on principles for the management of achondropla...

hrp0098p2-172 | Growth and Syndromes | ESPE2024

European Achondroplasia Forum: Are Current Outcome Measures for Achondroplasia Still Fit for Purpose in the Era of Medical Management?

Irving Melita , AlSayed Moeenaldeen , Baujat Genevieve , Ben-Omran Tawfeg , Boero Silvio , Cormier-Daire Valérie , Fauroux Brigitte , Fredwall Svein , Guillen-Navarro Encarna , Kunkel Phillip , Lampe Christian , Leiva-Gea Antonio , Maghnie Mohamad , Mohnike Klaus , Mortier Geert , Pejin Zagorka , Sessa Marco , Sousa Sérgio

Background: Achondroplasia requires lifelong multidisciplinary care. With the advent of targeted medical treatment, The European Achondroplasia Forum (EAF) reviewed existing health surveillance measures in achondroplasia to determine whether they are still relevant.Methods: An online questionnaire was used to assess health status monitoring both in routine clinical practice and in determining response to vosoritide, curr...